<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Velz J</submitter><funding>European Research Council</funding><pagination>1364</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11794601</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>Medulloblastoma is the most frequent malignant primary brain tumor in children. Despite recent advances in integrated genomics, the prognosis in children with high-risk medulloblastoma remains devastating, and new tumor-specific therapeutic approaches are needed. Here, we present an atlas of naturally presented T cell antigens in medulloblastoma. We map the human leukocyte antigen (HLA)-presented peptidomes of 28 tumors and perform comparative immunopeptidome profiling against an in-house benign database. Medulloblastoma is shown to be a rich source of tumor-associated antigens, naturally presented on HLA class I and II molecules. Remarkably, most tumor-associated peptides and proteins are subgroup-specific, whereas shared presentation among all subgroups of medulloblastoma (WNT, SHH, Grou</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics.</pubmed_title><pmcid>PMC11794601</pmcid><funding_grant_id>339842</funding_grant_id><pubmed_authors>Kapolou K</pubmed_authors><pubmed_authors>Weller M</pubmed_authors><pubmed_authors>Velz J</pubmed_authors><pubmed_authors>Rohrig A</pubmed_authors><pubmed_authors>Bozinov O</pubmed_authors><pubmed_authors>Craveiro RB</pubmed_authors><pubmed_authors>Frey BM</pubmed_authors><pubmed_authors>Grotzer M</pubmed_authors><pubmed_authors>Reinhard H</pubmed_authors><pubmed_authors>Weiss T</pubmed_authors><pubmed_authors>Kowalewski DJ</pubmed_authors><pubmed_authors>Eyrich M</pubmed_authors><pubmed_authors>Silginer M</pubmed_authors><pubmed_authors>Krayenbuhl N</pubmed_authors><pubmed_authors>Neidert MC</pubmed_authors><pubmed_authors>Walz JS</pubmed_authors><pubmed_authors>Medici G</pubmed_authors><pubmed_authors>Messing-Junger M</pubmed_authors><pubmed_authors>Freudenmann LK</pubmed_authors><pubmed_authors>Gauder M</pubmed_authors><pubmed_authors>Westphal M</pubmed_authors><pubmed_authors>Zeitlberger AM</pubmed_authors><pubmed_authors>Regli L</pubmed_authors><pubmed_authors>Scheid J</pubmed_authors><pubmed_authors>Wirsching HG</pubmed_authors><pubmed_authors>Rammensee HG</pubmed_authors><pubmed_authors>Ghasemi DR</pubmed_authors><pubmed_authors>Patterson AB</pubmed_authors><pubmed_authors>Sahm F</pubmed_authors><pubmed_authors>Nahnsen S</pubmed_authors><pubmed_authors>Dubbelaar M</pubmed_authors><pubmed_authors>Mohme M</pubmed_authors><pubmed_authors>Lamszus K</pubmed_authors><pubmed_authors>Rushing EJ</pubmed_authors><pubmed_authors>Beccaria K</pubmed_authors><pubmed_authors>Roth P</pubmed_authors><pubmed_authors>Sill M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics.</name><description>Medulloblastoma is the most frequent malignant primary brain tumor in children. Despite recent advances in integrated genomics, the prognosis in children with high-risk medulloblastoma remains devastating, and new tumor-specific therapeutic approaches are needed. Here, we present an atlas of naturally presented T cell antigens in medulloblastoma. We map the human leukocyte antigen (HLA)-presented peptidomes of 28 tumors and perform comparative immunopeptidome profiling against an in-house benign database. Medulloblastoma is shown to be a rich source of tumor-associated antigens, naturally presented on HLA class I and II molecules. Remarkably, most tumor-associated peptides and proteins are subgroup-specific, whereas shared presentation among all subgroups of medulloblastoma (WNT, SHH, Grou</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2025-04-04T07:26:39.679Z</modification><creation>2025-04-04T07:26:39.679Z</creation></dates><accession>S-EPMC11794601</accession><cross_references><pubmed>39904979</pubmed><doi>10.1038/s41467-025-56268-0</doi></cross_references></HashMap>